+49 761-389 49-0
Aberrant DNA methylation patterns found in cancer tissue are seen as the first and most persistent phenotypic expression biomarkers. Consequently, there is a major translational research effort to advance cell-free assay technologies for early cancer screening and for clinical diagnostics to support patient monitoring and treatment. However, accurate and precise measurement of methylated DNA markers across the genome or for specific genes that are found in plasma is technically complex and not yet standardized.
This webinar brings together a panel of academic, clinical, and industry experts in the field of methylated DNA testing who will discuss the promises and challenges of early cancer screening. The panel will discuss tissue plasma concordance, preanalytical variables, accurate measurement of methylated and unmethylated DNA, and the use of reference materials to help standardization.
Speaker:
• Dennis Lo, MD, PhD Director, Li Ka Shing Institute of Health Sciences Li Ka Shing Professor of Medicine, The Chinese University of Hong Kong
• Jimmy Lin, MD, PhD, MHS Chief Scientific Officer Freenome Company
• Yves Konigshofer, PhD Director, Technology Development, LGC Clinical Diagnostics
